$HIMS Many are overlooking the magnitude of this peptide news. This isn't just a simple headline news, it’s the activation of HIMS' core bull thesis. By vertically integrating with their own California manufacturing facility, HIMS has spent years preparing for this exact regulatory shift. If passed, this unlocks a high margin, proprietary peptide ecosystem that moves them far beyond simple distribution. This is the main thesis for HIMS. We probably will see HIMS trading in 3 digit easily.

@data168 I agree, I am not a memstock guy, but I think this changes the game for them

@data168 I agree this always was the main bull thesis. I think one big earnings and this flies back to all time high

@data168 it's like people forgot the peptide facility got bought in early 2025

@data168 $HIMS already has everything in place to capitalize on peptide opportunity: Massive reach via its DTC platform, California peptide facility, and Labs for evaluation/monitoring for peptides.

@data168 @grok what are the probabilities that this regulation is going to pass

@data168 @rmgtnic true

@data168 Absolutely. Unbelievable opportunity here with $HIMS

@data168 Hopefully by the summer we will see a 3 didgits